Long-acting C5 siRNA shows promise in IgAN

Researchers at CSPC Holdings Co. Ltd. and collaborators reported the development of a GalNAc-conjugated siRNA targeting complement component C5 (GalNAc-siRNA), designed for the treatment of kidney injury in IgA nephropathy (IgAN).